Assessing Market Potential

Leveraging a Scientific Approach to Assess the Clinical Landscape and Market Opportunity for Three Biologic Agents in the Heme Malignancy Space

The Challenge

The Challenge

An emerging oncology company with a robust pipeline of agents was seeking to evaluate the US oncology/hematology landscape across three preclinical assets, in furtherance of the company’s corporate interests and portfolio development. 

The company sought to assess the current and future competitive landscape, unmet clinical need, and prioritization of indications to pursue, in consideration of market potential and Phase 1/2 trial design. 

The IP Solution

The IP Solution

Taking a scientific approach to evaluating the competitive landscape, Innovation Partners provided  a thorough assessment of the current/future competitive landscape across potential indications by conducting a comprehensive literature review. 

Assumptions were tested by conducting primary market research with KOLs to understand perceptions and potential utilization scenarios.

The Result

The Results

Ultimately, the research resulted in the delivery of a dynamic sales forecasting model which was leveraged to determine the development strategy for the assets. Two of the three assets were moved into Phase 1 Studies, and the third was removed from consideration based on data provided in the forecasting models. 


Related Case Studies

Clinical Guideline Strategy

IP leveraged its Medical Affairs expertise and experience supporting more than 70 submissions to key oncology clinical practice guidelines to advocate for the inclusion of a test that predicts the benefit of therapy, resulting in broad and appropriate access for patients. 

Healthcare Policy Changes Interpreted in Real-Time

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

A Comprehensive Launch Strategy Leads to Broad Access

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.